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PRDM14 is a crucial regulator of mouse primordial germ cells (mPGCs), epigenetic repro-
gramming and pluripotency, but its role in the evolutionarily divergent regulatory network of
human PGCs (hPGCs) remains unclear. Besides, a previous knockdown study indicated that
PRDM14 might be dispensable for human germ cell fate. Here, we decided to use inducible
degrons for a more rapid and comprehensive PRDM14 depletion. We show that PRDM14 loss
results in significantly reduced specification efficiency and an aberrant transcriptome of
hPGC-like cells (hPGCLCs) obtained in vitro from human embryonic stem cells (hESCs).
Chromatin immunoprecipitation and transcriptomic analyses suggest that PRDM14 coop-
erates with TFAP2C and BLIMP1 to upregulate germ cell and pluripotency genes, while
repressing WNT signalling and somatic markers. Notably, PRDM14 targets are not conserved
between mouse and human, emphasising the divergent molecular mechanisms of PGC
specification. The effectiveness of degrons for acute protein depletion is widely applicable in
various developmental contexts.
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Gametes develop from primordial germ cells (PGCs), theembryonic precursors, which are apparently specified inapproximately week 2–3 human embryos1,2. While the
requirement for BMP and WNT signalling for PGC specification
is conserved between mouse and human3–5, the gene regulatory
network for hPGC fate has diverged6. Mouse PGCs (mPGCs) are
specified by three core transcription factors (TFs): Prdm1
(encoding BLIMP1), Prdm14, and Tfap2c (encoding AP2γ)7,8,
among which PRDM14 plays a central role; loss of Prdm14
abrogates mPGC specification9, while its overexpression is suffi-
cient to induce mPGC fate in vitro8.
During mPGC specification, PRDM14 induces upregulation
of germline-specific genes, assists BLIMP1-mediated repression
of somatic transcripts and initiates global epigenetic reprogr-
amming7,8,10,11. PRDM14 also has a significant role in pre-
implantation development12, as well as pluripotency induction
and maintenance in both mouse and human13–16. Indeed,
PRDM14 knockdown in hESCs led to a decrease in OCT4 levels
and elevated expression of lineage markers13,17,18.
Despite its critical function in mPGC specification, the role of
PRDM14 in hPGC development remains uncertain, due to its low
and potentially cytoplasmic expression in gonadal hPGCs3. Fur-
thermore, a partial PRDM14 knockdown suggested it might not
be important for hPGC specification in vitro19, within the TF
network for hPGC specification that has diverged significantly
from mouse1,6,20. In particular, SOX17 is a key determinant of
hPGC fate, acting upstream of BLIMP1 and TFAP2C3, but it is
dispensable for mPGC development21,22. Understanding whether
PRDM14 has a role in hPGC specification is critical towards
gaining insights on the molecular divergence between mouse and
human PGCs.
An inducible system for PRDM14 loss of function during
hPGCLC specification from hESCs is critical, since PRDM14 is
also vital for hESC pluripotency13. Accordingly, we combined
auxin- or jasmonate-inducible degrons23,24 with CRISPR/Cas9
genome editing25 to achieve fast, comprehensive and reversible
loss of endogenous PRDM14 protein. We reveal an indispensable
role for PRDM14 in germ cell fate, since loss of function affects
the efficiency of specification and results in an aberrant hPGCLC
transcriptome. Notably, PRDM14 targets are not conserved
between mouse and human, reflecting the evolutionary diver-
gence in the molecular network for PGC specification. The study
also illustrates the power of conditional degrons, which can be
widely used to study TFs during cell fate determination.
Results
Detection of PRDM14 expression during hPGCLC specifica-
tion. To follow PRDM14 expression during hPGCLC specification,
we appended Venus fluorescent protein to the C-terminus of
endogenous PRDM14 (Fig. 1a) in the background of NANOS3-
tdTomato hPGCLC-specific reporter5. PRDM14-T2A-Venus line
served for flow cytometry and fluorescence-activated cell sorting
(FACS) of PRDM14+ cells (Fig. 1b, c), while the fusion PRDM14-
AID-Venus reporter was used to confirm subcellular localisation of
PRDM14 (Fig. 1e), as well as for inducible protein degradation (see
below). We detected Venus fluorescence in targeted hESCs and
hPGCLCs but not in the parental control (Fig. 1b, c). Immuno-
fluorescence (IF) confirmed co-localisation of Venus and PRDM14
in nuclei of both hESCs and hPGCLCs (Figs. 1e, 2a). Importantly,
the majority of alkaline phosphatase (AP)+NANOS3-tdTomato+
hPGCLCs were PRDM14-Venus+ (Fig. 1c) and Venus+AP+ cells
specifically expressed key germ cell markers (Fig. 1d).
We also assessed PRDM14 expression in human gonadal
PGCs, and unlike some previous reports3,5, we detected PRDM14
not only in the cytoplasm, but also in the nucleus of both male
and female Wk7-9 hPGCs, (Supplementary Fig. 1A–D). Indeed,
some gonadal sections showed only nuclear PRDM14 (Supple-
mentary Fig. 1A, B). Nuclear localisation was also validated using
IF on FACS-purified AP+cKIT+ gonadal hPGCs (Supplementary
Fig. 1E). Based on the available data, PRDM14 localisation is
unlikely to be a consequence of stage or sex of hPGCs. However,
many more human foetal samples and stages will need to be
tested in the future to determine the dynamics, if any, of
PRDM14 localisation.
Next, we tracked PRDM14 expression dynamics upon hPGCLC
induction by time-course IF, using SOX17 (Fig. 2 and Supple-
mentary Fig. 2A), BLIMP1 (Supplementary Fig. 2B–D), TFAP2C
(Supplementary Fig. 2F) and OCT4 (Supplementary Fig. 2A, B) to
mark hPGCLCs. PRDM14 was uniformly expressed in 4i hESCs
(Fig. 1e) that are competent for hPGCLC fate3. However, 12 h
from the start of hPGCLC induction by cytokines, the levels of
PRDM14 declined significantly in SOX17+ or BLIMP1+ cells
(Fig. 2a), while the remaining PRDM14-Venus+ cells at 12 h were
SOX2+, and thus likely represented neighbouring pluripotent cells
(Supplementary Fig. 2E). The repression of PRDM14 in the
putative hPGCLCs was however transient, since we observed
specific re-expression of PRDM14 in ~25% of SOX17+ cells on
day 1 (D1); the proportion of PRDM14+SOX17+ cells continued
to increase progressively, reaching ~60% on D2, ~86% on D3,
~91% on D4 and ~93% on D5 (Fig. 2b). Many of the remaining
SOX17+PRDM14− or BLIMP1+PRDM14− cells might belong to
alternative lineages, as they lacked OCT4 expression (Supple-
mentary Fig. 2A, B). Indeed, PRDM14 marked the majority of
BLIMP1+OCT4+/SOX17+OCT4+ cells in D3–D5 embryoid
bodies (Fig. 2c and Supplementary Fig. 2D).
Interestingly, OCT4, while specific to germ cells from D3
onwards, was detected in most cells of the EB at 12 h and on D1,
as well as in many BLIMP1−/SOX17− cells on D2 (Supplemen-
tary Fig. 2A, B and ref. 3). Of note, high SOX2 and PRDM14
levels persisted in the control cell aggregates in the absence of
hPGCLC-inducing cytokines (Supplementary Fig. 2E).
We also assessed relative expression dynamics of PRDM14 and
KLF4, a naive pluripotency-related TF known to be specifically
expressed in hPGCs and hPGCLCs3,26, but repressed in mouse
germ cells27. Notably, KLF4 was not expressed in hPGCLC until
D3, and KLF4 expression followed that of PRDM14 (Supple-
mentary Fig. 2G).
Importantly, on D2, a higher proportion of BLIMP1+ than of
SOX17+ cells expressed PRDM14 (Fig. 2b and Supplementary
Fig. 2C), which agrees with the established order of SOX17
followed by BLIMP1 expression in hPGCLCs3. The majority of
BLIMP1+ cells are SOX17+ and are therefore likely to progress to
the upregulation of PRDM14. By contrast, some SOX17+ cells
might be at an earlier stage lacking BLIMP1 expression and thus
unlikely to have advanced far enough to express PRDM14.
The transient loss followed by re-expression of PRDM14 in
cells undergoing hPGCLC specification suggests that PRDM14
might have a vital role in this cell fate decision. We pursued this
possibility by using inducible degrons for an acute destabilisation
of the PRDM14 protein.
Inducible degrons allow efficient PRDM14 protein depletion.
Most inducible loss-of-function approaches act at the transcrip-
tional or post-transcriptional levels and often suffer from slow
and incomplete protein removal28–31. Since PRDM14 is one of
the core pluripotency factors in hESCs13, and exhibits dynamic
changes during hPGCLC induction, conventional knockout
approaches are unsuitable to study its functions in hPGCLCs. As
PRDM14 expression commences within 24 h of hPGCLC
induction, we decided to use conditional degrons32 to achieve
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Fig. 1 PRDM14-Venus knock-in reporters allow PRDM14 detection in hESCs and hPGCLCs. a Scheme of CRISPR/Cas9-mediated PRDM14 locus targeting
to generate T2A-Venus, AID-Venus or JAZ-Venus reporter versions. 5′ and 3′ arms—homology sequences, T2A—self-cleaving peptide, AID—auxin-
inducible degron, Venus—fluorescent gene, Rox—sequences for site-specific recombination recognised by the Dre enzyme, PGK-Puro—puromycin
resistance gene under the control of PGK promoter, ΔTK—truncated thymidine kinase gene, MC1-DTA—diphtheria toxin fragment A gene under the
control of MC1 promoter. Also see Fig. 3a. b, c Flow cytometry analysis showing Venus fluorescence in targeted hESCs and hPGCLCs compared with
negative control. Note that Venus fluorescence predominantly coincides with NANOS3-tdTomato signal, which marks hPGCLCs. d qPCR analysis on sorted
PRDM14-T2A-Venus+AP+ and double-negative cells from D4 EBs. Venus+AP+ population shows specific expression of germ cell markers. Data show
results from three technical replicates (also see Source Data file). e IF analysis (representative of >10 experiments) of PRDM14-AID-Venus in competent
hESCs showing co-localisation of PRDM14 and Venus fluorescence. Nuclei were counterstained by DAPI. Scale bar is 100 μm.
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fast, inducible and reversible PRDM14 depletion at the
protein level.
Auxin and jasmonate-inducible degrons (AID and JAZ,
respectively), are plant pathways for ligand-induced targeted
protein degradation23,24. To harness AID and JAZ degrons in
hESCs and hPGCLCs, we used CRISPR/Cas9 to tag the C-
terminus of the endogenous PRDM14 with AID or JAZ degron
sequences (see below) fused to Venus (Fig. 3a). Next, we
employed the PiggyBac transposon system33 to deliver codon-
optimised transgenes encoding cognate hormone receptors from
rice (Oryza sativa): TIR1 for AID and COI1B for JAZ, allowing
target degradation upon administration of auxin (indole-acetic
acid, IAA) or coronatine (Cor), respectively24,34. Note that we
fused COI1B with TIR1 F-box domain (resulting in Fb-TIR1-
COI1B) to ensure better integration into human SCF (SKP1,
CUL1 and F-box) E3 ubiquitin–ligase complex, as reported
previously24.
For AID, we chose the 44-amino-acid (residues 71–114)
version of the Arabidopsis thaliana AID tag (AtAID44) that was
used successfully elsewhere34,35. Since the JAZ system has not
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Fig. 2 PRDM14-Venus knock-in reporter detects the dynamics of specific PRDM14 expression in hPGCLCs. a Time-course IF analysis (representative of
two hPGCLC inductions) showing PRDM14 expression in embryoid body (EB) sections throughout hPGCLC specification from PRDM14-AID-Venus fusion
reporter cell line. hPGCLCs were induced by cytokines and EBs were collected at 12 h, and on D1-D5. Representative images for 12 h, D1, D2 and D4 are
shown. hPGCLCs were marked by SOX17 and highlighted by a dashed line. Arrows show examples of SOX17+ cells that are PRDM14-negative at 12 h and
PRDM14-positive on D1 of differentiation. Scale bar is 60 μm. b Quantification of results from a and Supplementary Fig. 2A, including the D1–D5 time
points. Data show the percentage of PRDM14-Venus+SOX17+ cells as mean ± SD of n= 11 EB sections from two hPGCLC inductions. c Quantification of
results from (Supplementary Fig. 2A) showing the percentage of PRDM14-Venus+SOX17+OCT4+ cells as mean ± SD of n= 3 EB sections from one
hPGCLC induction.
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been validated as extensively as AID, we performed additional
optimisation experiments (Supplementary Fig. 3). We compared
the best performing degron sequences from24, namely OsJAZ33
(version 6-Os33) and NLS-OsJAZ33 (version 7), with a slightly
longer OsJAZ43 degron sequence (without NLS). For this, HEK-
293T cells were infected with viral constructs harbouring GFP
fused to respective degron sequences and treated with Cor or
DMSO (control). GFP depletion at 2, 4 and 24 h was monitored
by flow cytometry (Supplementary Fig. 3A). This showed that the
longer degron sequence (OsJAZ43) is superior to OsJAZ33 and
slightly better than NLS-OsJAZ33 in the efficiency and speed of
GFP depletion (Supplementary Fig. 3A). This suggests that
OsJAZ43 is more versatile and can allow depletion of both nuclear
and cytoplasmic proteins.
To further test if JAZ could be efficiently used in our system,
we generated hESCs expressing a PiggyBac-delivered construct
(Supplementary Fig. 3B), where GFP was fused to the best
OsJAZ43 degron sequence and an NLS, to better model the
depletion of TFs such as PRDM14. The construct also harboured
the Fb-TIR1-COI1B hormone receptor. GFP signal started
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Fig. 3 Auxin- and jasmonate-inducible degrons allow fast and homogenous PRDM14 protein depletion. a Scheme of AID and JAZ systems and the
derivation of PRDM14-AID-Venus and PRDM14-JAZ-Venus cell lines. SKP1, CUL1, RBX1 and F-box (TIR1 or COI1B) are the subunits of the SCF E3
ubiquitin–ligase complex. In the presence of IAA (for AID) or Cor (for JAZ) the target associates with the E3 ligase via a cognate hormone receptor (F-box
protein); the recruited E2 ubiquitin-conjugating enzyme polyubiquitinates the target, which results in its proteasomal degradation24,80. For cell line
generation, the cells were first transfected with two plasmids: (1) Cas9-encoding plasmid25 with a gRNA sequence targeting the vicinity of the PRDM14
stop codon; (2) HDR (homology-directed repair) template (also see Fig. 1a) containing the sequences to be appended by KI, flanked by two 800-bp
homology arms; MC1-DTA was added to reduce random integration5. The knocked-in sequences were: AID (AtAID44) or JAZ (OsJAZ43) followed by
Venus and a positive/negative PGK-puromycin-ΔTK selection cassette flanked by Rox sites to allow excision by Dre5. Correct homozygous clones were
transfected with PiggyBac constructs encoding the corresponding hormone receptor (TIR1 for AID and Fb-TIR1-COI1B for JAZ) under the control of the
CAG promoter followed by an IRES and a hygromycin resistance gene. The homogeneity of myc-TIR1 or HA-COI1B expression in selected clones was
checked by IF (see b, c). b IF (representative of three experiments) showing PRDM14, NANOG and TIR1 (myc-tagged) expression and PRDM14-AID-Venus
depletion upon 25min of IAA treatment. Nuclei were counterstained by DAPI. Scale bar is 100 μm. c IF (representative of three experiments) showing
PRDM14-Venus, OCT4 and COI1B (HA-tagged) expression and PRDM14-JAZ-Venus depletion upon 2 days of Cor treatment. Nuclei were counterstained
by DAPI. Scale bar is 100 μm.
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decreasing 3 h after Cor administration (Supplementary Fig. 3C)
and 99% of cells were GFP-negative after one passage in Cor
(Supplementary Fig. 3D). Based on these results, we used OsJAZ43
and Fb-TIR1-COI1B combination to deplete PRDM14.
First, we tested AID- or JAZ-mediated PRDM14 depletion in
hESCs by growing them with or without corresponding
hormones and performing IF (Fig. 3b, c and Supplementary
Fig. 4). PRDM14 and Venus fully colocalised and were both
reduced upon the addition of IAA or Cor in hormone-sensitive,
but not in parental lines (Fig. 3b, c and Supplementary
Fig. 4A–D). Crucially, the AID system allowed reduction of
Venus fluorescence to negligible levels, comparable with cells
lacking the Venus knock-in (Supplementary Fig. 4C). Time-
course IF in hESCs revealed a rapid onset of PRDM14-AID-
Venus depletion within 10 min of IAA treatment, reaching
homogeneity within 25 min (Fig. 3b and Supplementary Fig. 4E).
In the case of the JAZ degron, however, residual PRDM14-JAZ-
Venus signal was detectable even after 2 days of Cor treatment
(Fig. 3c and Supplementary Fig. 4D). Both systems are never-
theless reversible24,34, and IAA wash-off restored PRDM14 levels
in less than 2 h (Supplementary Fig. 4F). Altogether, inducible
degrons allow fast and reversible PRDM14 depletion, with AID
being superior in terms of speed and efficiency.
Inducible PRDM14 degradation reduces hPGCLC specifica-
tion. Next, we addressed the importance of PRDM14 for
hPGCLC specification by adding IAA or Cor at the onset of
hPGCLC differentiation (D0), followed by measuring the induc-
tion efficiency on D4 by recording the percentage of NANOS3-
tdTomato+AP+ cells (Fig. 4a). Notably, PRDM14 depletion using
both approaches resulted in a significant reduction of hPGCLC
induction efficiencies (by 70% and 30–60%, respectively) (Fig. 4b,
c and Supplementary Fig. 5A–C). The effect was more pro-
nounced in the case of the AID system, presumably due to its
higher efficiency and faster kinetics of PRDM14 depletion.
Therefore, we focused on the AID system to study PRDM14
further. Crucially, the observed phenotype was replicated using a
PRDM14-AID in another hESC line (Supplementary Fig. 5D).
To further test AID efficacy in this context, we induced
degradation of SOX17, a known hPGC and definitive endoderm
(DE) regulator3,20,36. IAA addition fully abrogated hPGCLC and
DE specification (Supplementary Fig. 5E–G), confirming the key
roles of SOX17 in these lineages.
To establish the time when PRDM14 is essential for hPGCLC
specification, we performed a time-course of IAA supplementa-
tion. We performed depletion of PRDM14 by adding IAA
starting on D0, D1 or D2, followed by analysis on D4. We noted a
strong phenotype with reduction in hPGCLC specification
(Fig. 4d). By contrast, the addition of IAA on D3 had no
detectable effect on the number of NANOS3-tdTomato+AP+
cells (Fig. 4d). This suggests that either PRDM14 is dispensable
after D2 or that its depletion at later time points does not affect
hPGCLC numbers, although transcriptional or epigenetic con-
sequences cannot be excluded. Altogether this points to an early
critical role of PRDM14 in hPGCLC specification.
PRDM14 is highly expressed in human PGC-competent
pluripotent cells, unlike in mice, where it is repressed at the
equivalent stage3,37. Notably, however, PRDM14 depletion in 4i
hESCs for one passage prior to hPGCLC induction (Supplemen-
tary Fig. 5H) had no effect on hPGCLC specification (Supple-
mentary Fig. 5I), indicating no detectable involvement of
PRDM14 in the maintenance of competence for hPGCLC fate.
To determine if PRDM14 is required for the acquisition of
competence, we induced competence for hPGCLCs in hESCs via
pre-mesendoderm (preME), which transiently displays hPGCLC
potential5. However, when IAA was added to the preME medium
and washed off before hPGCLC induction (Supplementary
Fig. 5H), we observed no effect on hPGCLC specification
efficiency (Supplementary Fig. 5J). Altogether, these data
demonstrate that PRDM14 is important for hPGCLC specifica-
tion but is dispensable for the acquisition and maintenance of the
hPGCLC-competent state. Furthermore, this suggests a probable
specific and direct requirement for PRDM14 in hPGCLC
induction, which might not simply result from pluripotency
disruption in the starting cell population.
Restored PRDM14 levels rescue hPGCLC differentiation. To
confirm the specificity of the observed phenotype, we attempted
to rescue the endogenous PRDM14 depletion with ectopic
PRDM14, using the ProteoTuner system, whose kinetics is
comparable with that of AID38. PRDM14 transgene was fused to
a destabilisation domain (DD) and thus continuously degraded
by the proteasome but stabilised by Shield-1 ligand38,39. Inter-
estingly, overexpression of PRDM14 on D0, but not on D1 could
fully rescue hPGCLC specification efficiency and even enhanced
hPGCLC specification compared with “no IAA” control (Fig. 5a).
This suggests that the transient PRDM14 repression observed at
the onset of hPGCLC specification (Fig. 2b) is not prerequisite for
germ cell induction and that despite low PRDM14 expression in
SOX17/BLIMP1+ cells on D0, it is apparently critical for
hPGCLC induction.
We then asked if we could restore the endogenous PRDM14
levels by blocking auxin perception. To achieve this, we designed
an AID-JAZ degron switch, where PRDM14-AID-Venus is
degraded by IAA supplementation, while TIR1 is fused to JAZ
and thus depleted by Cor (Fig. 5b). IF analysis in hESCs
confirmed that simultaneous administration of both IAA and Cor
desensitised hESCs to IAA via TIR1 degradation and replenished
the PRDM14-Venus pool (Fig. 5c). In line with previous
experiments, these cell lines also showed decreased hPGCLC
specification efficiency upon IAA treatment (Fig. 5d). Crucially,
in the presence of both IAA and Cor, hPGCLC differentiation
efficiency was significantly restored (Fig. 5d). Interestingly,
similar to PRDM14-DD overexpression above (Fig. 5a), sig-
nificant rescue was only achieved on D0, but not on D1–D2
(Fig. 5e), confirming the early role of PRDM14 in hPGCLC
specification. Overall, these data prove the causative role of
PRDM14 depletion in hPGCLC induction phenotype and
exemplify the use of orthogonal degron approaches for rescue
design.
PRDM14-deficient hPGCLCs show aberrant transcriptome.
Next, we examined the transcriptome of PRDM14-deficient
hPGCLCs by performing RNA-sequencing (RNA-seq) on
NANOS3-tdTomato+AP+ hPGCLCs differentiated with or
without IAA for 4 days from two hormone-sensitive clones and
the parental control lacking TIR1. We also addressed the role of
PRDM14 in pluripotency regulation, by analysing the tran-
scriptome of AP+ competent hESCs grown with or without IAA
for one passage (3 days). Importantly, the parental (“no TIR1”)
control showed no differentially expressed genes (DEGs) in IAA-
treated hESCs, and only two upregulated genes in hPGCLCs
(CYP1B1 and LRAT), indicating minimal non-specific effects of
auxin on the target cells’ transcriptome (Supplementary Data 1).
RNA-seq on PRDM14-depleted hESCs identified 106 upregu-
lated and 64 downregulated genes (Fig. 6a and Supplementary
Data 1). Crucially, our findings concur with a previous study
on PRDM14 in different hESC lines and culture conditions13
(Fig. 6c), with downregulation of pluripotency genes (e.g. OCT4,
NANOG, TDGF1 and GAL), and upregulation of differentiation
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markers, particularly of the neural lineage (e.g. MAP2, MAP6 and
SOX2) (Fig. 6a, Supplementary Fig. 6E and Supplementary
Data 1). Gene ontology (GO) analysis reflected reduction in
self-renewal (enriched downregulated term “somatic stem cell
maintenance”) and upregulation of pro-differentiation genes
(enriched terms “nervous system development” and “embryonic
pattern specification”) (Fig. 6f).
Notably, there was a stronger response to PRDM14 loss in
hPGCLCs, with 1017 upregulated and 460 downregulated genes
in “+IAA” vs “no IAA” samples (Fig. 6b), and only a small
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overlap between the affected genes in hESCs and hPGCLCs
(Supplementary Data 1). Principal component analysis (PCA)
and unsupervised hierarchical clustering of hPGCLC transcrip-
tome confirmed that parental control, irrespective of IAA
treatment, clustered with untreated hormone-sensitive clones,
and away from the PRDM14-depleted hPGCLCs that clustered
together (Fig. 6d and Supplementary Fig. 6A). Crucially,
PRDM14-deficient hPGCLCs showed downregulation of many
key hPGC- and pluripotency-related genes, including UTF1,
NANOG, NANOS1, LIN28A and TRIM28. GO analysis showed
enrichment of protein biosynthesis-related processes, somatic
stem cell population maintenance and negative regulation of
WNT signalling (Fig. 6h). Gene set enrichment analysis (GSEA)
against 123 core PGC genes defined previously5, showed lower
enrichment score of mutant hPGCLCs compared with the control
(Supplementary Fig. 6B). The levels of key hPGC regulators,
SOX17 and PRDM1, however did not change (Fig. 6e and
Supplementary Fig. 6D), which is consistent with their upregula-
tion prior to PRDM14 in nascent hPGCLCs (Fig. 2, Supplemen-
tary Fig. 2A, B and ref. 3). Crucially, top changes in gene
expression were also confirmed by qPCR using independent
hPGCLC inductions (Fig. 6e and Supplementary Fig. 6D). qPCR
analysis also showed downregulation of KLF4 in PRDM14-
depleted hPGCLCs (Fig. 6e), which, together with the observation
that PRDM14 expression precedes that of KLF4 (Supplementary
Fig. 2G), might suggest that PRDM14 could be upstream of KLF4
in hPGCLCs. Ectopic PRDM14 could partially revert the
transcriptional changes in mutant hPGCLCs (Supplementary
Fig. 6C), in line with rescued hPGCLC specification phenotype
(Fig. 5a).
GO analysis on genes derepressed in PRDM14-deficient
hPGCLCs identified enrichment of terms related to WNT
signalling, as well as heart and nervous system development
(Fig. 6g). A similar response occurs in hPGCLCs specified
without BLIMP1 or TFAP2C20,26. Indeed, pairwise comparisons
revealed a significant overlap between both up- and down-
regulated targets, suggesting potential combinatorial roles of
PRDM14 with BLIMP1 and TFAP2C. Accordingly, 115 genes
were downregulated in all three mutants (including germ cell
markers UTF1, NANOG, AKAP12, NANOS1 and TRIM28), while
281 shared upregulated genes were mostly implicated in
morphogenesis, WNT signalling, as well as cell migration and
adhesion (Supplementary Fig. 6F–G and Supplementary Data 2).
PRDM14 regulates gene expression through promoter binding.
To identify direct targets of PRDM14 in hPGCLCs and hESCs, we
performed chromatin immunoprecipitation (ChIP) with high-
throughput sequencing (ChIP-seq). We took advantage of the
PRDM14-AID-Venus line to use a ChIP-grade anti-GFP anti-
body for PRDM14-Venus immunoprecipitation, which proved
more efficient than anti-PRDM14 antibodies (Supplementary
Fig. 7A). Importantly, auxin treatment led to a significant loss of
signal (Supplementary Fig. 7A), which allowed us to use ChIP-seq
on IAA-treated hESCs as a control.
Overall, ChIP-seq identified 6486 consensus PRDM14 peaks:
4206 in hPGCLCs and 3319 in hESCs (Supplementary Data 3). k-
means clustering partitioned the dataset into five distinct clusters
(Fig. 7a), separating peaks specific to hESCs (742 peaks, cluster 4)
or hPGCLCs (1331 peaks, cluster 5) or shared between the two
(clusters 1–3). Note that the strongest ChIP-seq enrichment
persisted in IAA-treated hESCs (clusters 1–2) with 1728/3319
hESC binding sites detectable in hESC+ IAA, albeit with
significantly lower signal (Fig. 7a and Supplementary Data 3).
Such persistent regions might be more tightly bound, and/or
require longer auxin exposure to eliminate PRDM14 binding
completely.
Notably, PRDM14 in both hESCs and hPGCLCs predomi-
nantly binds within 1 kb of transcription start sites (TSS)
(Supplementary Data 3), with ~30% of peaks spanning annotated
promoters (Fig. 7b), which agrees with a previous ChIP-seq in
hESCs13. By contrast, PRDM14 binds predominantly to distal
genomic regions in mice, and only 4–10% of peaks are located
within 1 kb from the TSS in mESCs16,40.
Motif analysis41 confirmed that the conserved PRDM14 motif
was top ranking in both hESCs and hPGCLCs (Fig. 7c). Notably,
TFAP2C motif was the second most enriched within hPGCLC-
specific targets, suggesting cooperation between the two factors
(Fig. 7c), consistent with the overlapping targets from RNA-seq
(Supplementary Fig. 6F). We also found significant enrichment of
BLIMP1 and SOX motifs in hPGCLCs, whereas unique hESC
peaks were enriched in the OCT4-SOX2 motif (Fig. 7c).
Altogether, this indicates that PRDM14 co-occupies genomic
targets with core TFs specific to hPGCs or pluripotent cells,
respectively.
Next, we correlated ChIP-seq peaks mapping within 100 kb of
the TSS with the corresponding changes in gene expression from
RNA-seq (Fig. 7d, Supplementary Fig. 6H and Supplementary
Data 3). In hPGCLCs, 314 peaks were associated with 168 (17%)
upregulated genes and 93 peaks with 47 (10%) downregulated
genes (Supplementary Data 3). GO analysis confirmed that genes
related to WNT signalling, heart and brain development are
among the direct PRDM14 targets (Supplementary Fig. 7B). The
Fig. 6 RNA-seq reveals transcriptional changes in PRDM14-deficient hESCs and hPGCLCs. a Volcano plot showing down- (log2FC < (−0.5), padj <
0.05) and upregulated (log2FC > 0.5, padj < 0.05) genes in hPGC-competent hESCs upon PRDM14 loss. PRDM14-AID hESCs were treated with IAA for
one passage (3 days) and sorted as AP+ cells for RNA-seq along with “no IAA” control. b Volcano plot showing down- (log2FC < (−0.5), padj < 0.05) and
upregulated (log2FC > 0.5, padj < 0.05) genes in hPGCLCs upon PRDM14 loss. PRDM14-AID hPGCLCs were specified with or without IAA for 4 days and
sorted as NANOS3-tdTomato+AP+ cells for RNA-seq along with “no IAA” control. c Boxplot overlaying down- (log2FC < (−0.5), padj < 0.05) and
upregulated (log2FC > 0.5, padj < 0.05) genes upon PRDM14 knockdown in conventional hESCs (microarray data from13) and RNA-seq analysis in
PRDM14-AID-depleted PGC-competent (4i) hESCs from this study. The distance from the bottom to the upper line of the box spans the interquartile range
(IQR), the horizontal line in the box indicates the median of the dataset, while the whiskers show ±1.5× IQR. Note that the majority of differentially
expressed genes show consistent changes. d Principal component analysis (PCA) of hPGCLC RNA-seq samples. PRDM14-depleted hPGCLCs (cl11 and cl21;
highlighted in red) separate from the other samples along principal component 1 (PC1). e qPCR validation of selected DEGs from RNA-seq. hPGCLCs from
cl11 and cl21 were sorted as NANOS3-tdTomato+AP+ cells, while soma denotes the double-negative population from the same experiments. Strongly
upregulated genes are plotted separately. Data show gene expression relative to no IAA hPGCLCs and normalised to GAPDH, mean ± SEM of n= 5 for
SOX17 and VENTX, mean ± SEM of n= 3 independent experiments for NANOS3, BLIMP1, TFAP2C, KLF4 or n= 2 for other genes. Statistical significance of
hPGCLC no IAA vs. +IAA was assessed by multiple unpaired t-tests yielding two-tailed P values: KLF4 **(P= 0.0054), NANOG **(P= 0.0053), NANOS3
*(P= 0.0452), VENTX ****(P < 0.0001). The parental (“no TIR1”) control is shown in Supplementary Fig. 6D. f Gene ontology (GO) analysis on down- and
upregulated genes in PRDM14-deficient hESCs. Top non-redundant GO terms are shown as −log10(p value). g GO analysis on down- and upregulated
genes in PRDM14-deficient hPGCLCs. Top non-redundant GO terms are shown as −log10(p value). For complete list of GO terms see Supplementary
Data 6.
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hESC-specific targets included SOX2, ERBB3 and GBX2, while
hPGCLC-specific peaks were found near SOX17, TFAP2C and
NANOS3 among others (Fig. 7e, f). Whereas PRDM14 binds to
the regulatory elements of SOX17, PRDM14 depletion did not
significantly affect SOX17 expression in hPGCLCs (Fig. 6e and
Supplementary Data 1) presumably because other factors sustain
its expression.
Distinct molecular functions of PRDM14 in mouse and
human. Next, we asked if the molecular roles of PRDM14 are
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conserved between mouse and human, by comparing the protein-
coding transcriptomes of PRDM14-AID hESCs and hPGCLC,
with the equivalent mouse Prdm14−/− cells11 (Supplementary
Fig. 8A, B and Supplementary Data 4). PGC-competent mouse
epiblast-like cells showed very few DEGs since Prdm14 is
repressed in these cells11. Only two genes (CDH4 and HS6ST2)
were derepressed in both mESCs and hESCs, and three genes
(DNMT3B, SPRY4 and FHL1) showed opposite changes, probably
reflecting the broader differences between mESCs and hESCs42.
Comparison of PRDM14-depleted hPGCLCs with D6 Prdm14−/−
mPGCLC identified a limited subset of potentially conserved
PRDM14 targets: 36 up- and 13 downregulated genes (Supple-
mentary Fig. 8A), but none have hitherto been implicated in germ
cell biology. Furthermore, the expression of 39 DEGs was anti-
correlated in hPGCLC and mPGCLCs (Supplementary Fig. 8A).
In mPGCs, PRDM14 is key to epigenetic reprogramming,
ensuring DNA demethylation through repression of Uhrf1 and
loss of H3K9me2 through Ehmt1 downregulation9. hPGCs
display similar hallmarks of epigenetic reprogramming, asso-
ciated with repression of UHRF1 and EHMT2 (ref. 26). While by
RNA-seq we did not detect changes in UHRF1 or EHMT2
expression in PRDM14-deficient hPGCLCs, we verified UHRF1
and H3K9me2 levels by IF (Supplementary Fig. 8C, D), to exclude
regulation at the protein level, as observed in other contexts43–45.
This showed an increase in the proportion of UHRF1+
proliferating D4 hPGCLCs upon PRDM14 depletion, potentially
suggesting a conserved regulation (Supplementary Fig. 8C, G).
The effect was, however, heterogeneous and there was no
significant difference in mean fluorescence intensities of UHRF1
in proliferating hPGCLCs induced with or without IAA
(Supplementary Fig. 8E). We did not detect significant retention
of H3K9me2 in PRDM14-deficient hPGCLCs (Supplementary
Fig. 8D, F, H). Overall this could suggest that PRDM14 is less
critical for epigenetic reprogramming in hPGCs than it is in the
mouse. However, D4 hPGCLCs model pre-migratory germ cells3,
which might be too early to detect potential defects in epigenetic
resetting caused by PRDM14 depletion.
PRDM14 alone is sufficient to induce mPGCLCs fate8;
however, this was not the case for hPGCLC specification using
either doxycycline-inducible or ProteoTuner systems (Supple-
mentary Fig. 8I), consistent with the observation that upregula-
tion of SOX17, BLIMP1 and TFAP2C precede PRDM14
expression (Fig. 2 and Supplementary Fig. 2). Altogether
PRDM14 evidently plays an important role shortly after the
initiation of hPGCLC fate, but its function is distinct from that
in mPGCs.
Discussion
Using two acute protein depletion strategies, combined with
rescue, transcriptomic and ChIP-seq experiments, we demon-
strate that PRDM14 is required for hPGCLC specification and
represses somatic differentiation while promoting germline fate
(Supplementary Fig. 9). Strikingly, the molecular function of
PRDM14 in the human germline has diverged significantly
compared with mPGCs. Indeed, the sets of targets regulated by
PRDM14 in the two species are vastly different (Supplementary
Fig. 8A, B) and, unlike in the mouse8, PRDM14 alone cannot
induce hPGCLCs (Supplementary Fig. 8D). The regulatory net-
work for hPGC specification is altogether distinct from that in
mice, with the recently established critical role of SOX17, and the
notable repression of SOX2 (refs. 3,20). Our study of PRDM14
provides further insights on the divergence of the molecular basis
of germ cell fate determination in mouse and human.
PRDM14 is specifically upregulated in the nucleus of nascent
hPGCLC, its expression follows that of SOX17, BLIMP1 and
TFAP2C, but precedes the upregulation of KLF4 (Fig. 2 and
Supplementary Fig. 2). PRDM14 depletion strongly reduces the
efficiency of germ cell specification (Fig. 4) and results in an
aberrant transcriptome of the PRDM14-deficient hPGCLCs
(Fig. 6). Conversely, PRDM14 overexpression on D0 of induction
rescues and even enhances hPGCLC specification (Fig. 5). Since
hPGCLC induction is probably not a fully synchronous process, it
is possible that PRDM14 overexpression in cells that start upre-
gulating SOX17 and BLIMP1 might enhance their propensity to
adopt hPGCLC fate through accelerating the expression of
PRDM14 target genes, which perhaps helps consolidating germ
cell identity.
The effects of PRDM14 depletion during hPGCLC specifica-
tion, resemble those observed upon the loss of TFAP2C or
BLIMP1 (Supplementary Fig. 6F). Furthermore, ChIP-seq ana-
lysis revealed high enrichment of TFAP2C and BLIMP1 motifs
within hPGCLC-specific PRDM14 targets (Fig. 7c), which sug-
gests combinatorial roles of the three regulators during the
induction of hPGC-specific genes and the repression of somatic
markers. However, unlike in mPGCs11,46, many prominent germ
cell genes, such as TFAP2C, PRDM1 and DND1, are not the
targets of PRDM14 in hPGCLCs. Furthermore, while the
PRDM14 motif is conserved, PRDM14 binds predominantly to
gene promoters in hESCs and hPGCLCs13 (Fig. 7b), but to distal
regulatory elements in mice16,40. The notable lack of overlap
might be dictated by different protein partners or by the diver-
gence of the protein itself, although there is significant functional
conservation of the protein, as human PRDM14 rescues the lack
of its mouse orthologue in mESCs15.
The context-dependent roles of PRDM14 are also exemplified
by distinct set of target genes in hESCs, where it cooperates with
OCT4 and SOX2 to sustain pluripotency, and limits neuronal
differentiation (Fig. 6a, Supplementary Figs. 6E, 7C and 9). This
and other studies highlighted the divergent roles of PRDM14 in
mouse and human pluripotent cells13,15,16,40. Furthermore, there
are significant human–mouse differences during early embryo
development, at the time of PGC specification47,48; altogether
these differences likely contribute to the species-specific modes of
PGC specification. Notably, we found an even more pronounced
transcriptional phenotype upon PRDM14 loss in hPGCLCs than
in hESCs (Fig. 6). Note that hESCs were, however, in a ‘steady
state’ of self-renewal, while hPGCLCs were undergoing cell fate
Fig. 7 ChIP-seq analysis shows hESC- and hPGCLC-specific PRDM14 binding patterns. a Consensus PRDM14-bound peaks (6486) are separated into
five clusters by k-means clustering. The ChIP signals (counts per million per 10-bp bin) of each peak are shown in the clustered heatmaps (bottom panel).
The profile plots (top panel) show the average ChIP signals of each cluster. b Distribution of clustered PRDM14 peaks in the genome. Note that PRDM14
predominantly binds to promoters. c Top-ranking motifs identified by HOMER de novo motif analysis within hESC- and hPGCLC-specific PRDM14 peaks
(FC > 3, p value < 0.0001). d Scatter plots highlighting examples of direct PRDM14 targets in hESCs and hPGCLCs. Direct targets were defined as genes
with at least one PRDM14 ChIP-seq peak (q value < 0.05) within 100 kb of the TSS and showing significant changes in expression upon IAA treatment
(log2FC < (−0.5) or >0.5 and padj < 0.05). e PRDM14 binds to regulatory regions of key hPGC-related genes. The scatter plot shows differential PRDM14
peaks (FC > 3, p value < 0.0001) correlated to genes differentially expressed between hESCs and hPGCLCs (log2FC < (−0.5) or >0.5 and padj < 0.05).
f Examples of loci bound by PRDM14 in hPGCLCs and hESCs. Note that the peak downstream of ERBB3 is preserved in hESCs after IAA treatment. PRDM14
peaks in indicated samples were visualised using IGV software. PRDM14 ChIP-seq dataset from ref. 13 was added for comparison.
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transitions at the time of PRDM14 depletion. The persistence of
PRDM14 at some loci even after 3 days of IAA treatment
(Fig. 7a), is reminiscent of a significant (27%) retention of CTCF-
AID peaks that were reported after 2 days of exposure to IAA34.
Since most other inducible loss-of-function approaches display
lower efficiency and slower kinetics, it is likely that they may
result in even slower protein depletion from chromatin.
The distinct roles of PRDM14 in mouse and human PGCs,
further illustrate the impact of the species-specific regulatory
networks for PGC fate. For example, expression of SOX17 and
SOX2 is mutually exclusive in germ cells of human and mouse,
respectively. Whereas SOX17 is essential for hPGC fate3, SOX2
promotes mPGC specification and survival49. By contrast,
repression of SOX2 is apparently prerequisite for the initiation of
hPGCLC fate1, since ectopic expression of SOX2 abrogates
hPGCLC specification50. In the absence of BMP signalling, which
initiates hPGCLC specification, high expression of SOX2 and
PRDM14 is maintained (Supplementary Fig. 2). It is possible that
PRDM14 expression in the hPGCLC-competent cells is down-
stream of SOX2. The repression of SOX2 upon the initiation of
hPGCLC in response to BMP signalling might therefore explain a
transient loss of PRDM14. Indeed, in hESC where SOX2 binds to
PRDM14 promoter51, loss of SOX2 leads to PRDM14 down-
regulation52. The observed re-expression of PRDM14 in hPGCLC
follows after the upregulation of SOX17 and BLIMP1 at the onset
of hPGCLC specification (Fig. 2 and Supplementary Fig. 2),
which suggests a molecular shift in the regulation of PRDM14
expression in germ cells.
In mPGCs, PRDM14 promotes DNA demethylation, in part
by repressing Uhrf1, and initiates the reduction of H3K9me2
through Ehmt1 downregulation9. How the TF network might
control the epigenetic resetting in hPGCs is less clear, but some
essential features of epigenetic reprogramming are evident in
hPGCs, including the repression of UHRF1 and EHMT2
(ref. 26). While there was a trend towards derepression of
UHRF1 in a subset of PRDM14-deficient hPGCLCs (Supple-
mentary Fig. 8C), we did not observe changes in H3K9me2
levels. Unfortunately, currently available hPGCLCs only reca-
pitulate pre-migratory hPGCs, and do not show significant
epigenetic changes as observed in later-stage in vivo germ
cells1. Therefore, it is difficult to comprehensively assess the
influence of PRDM14 loss on epigenetic resetting in the human
germline. Further studies are required to establish how pre-
cisely the epigenetic resetting is initiated in hPGCs and
establish whether or not PRDM14 has an important role in this
critical process.
Our study shows the importance of the use of rapid and
comprehensive PRDM14 depletion for the phenotype unmasking.
A previous study of PRDM14 in hPGCLCs used a partial
knockdown at a later time-point (D2 BLIMP1+SOX17+ pre-
cursors), where the homogeneity and speed of PRDM14 depletion
was not monitored19. We demonstrate the utility of AID and JAZ
degrons to deplete endogenous proteins to study human cell fate
decisions. Simultaneous use of both degrons allows independent
control of two proteins, and the construction of degron switches
as shown here (Fig. 5b, d). The knock-in of AID/JAZ together
with a fluorescent reporter facilitates protein expression analysis
and allows the use of the anti-GFP (or other epitope tags) anti-
body for IF and ChIP. Furthermore, tissue-specific TIR1
expression can allow spatial control over protein stability, as
shown in Caenorhabditis elegans and Drosophila melanogaster
without detectable side effects53,54.
Neither mouse nor human adult tissues express PRDM14
except in some types of cancer14,55, indicating the importance of
studying the role of PRDM14 in normal embryogenesis. Inducible
degrons offer a more precise control over proteins when studying
the roles of critical TFs undergoing dynamic changes during
normal and malignant development.
Methods
Human embryonic stem cell culture. PGC-competent 4i hESCs (H9 (ref. 56),
WIS2-NANOS3-T2A-tdTomato (N3)5 and cell lines derived from them) were
cultured as in ref. 3 on irradiated mouse embryonic fibroblasts (MEFs) (Global-
Stem) in 4i medium (Table 1). Media were replaced every day. hESCs were pas-
saged by single-cell dissociation using 0.25% Trypsin-EDTA (GIBCO). 10 μM
ROCK inhibitor (Y-27632, TOCRIS) was added for 24 h after passaging.
Conventional hESCs (used for hPGCLC differentiation via preME) were grown
in Essential 8 (E8)57 in plates pre-coated with 5 μg/ml vitronectin for at least 1 h.
Media were replaced every day. Cells were passaged in clumps using 0.5 mM EDTA
in PBS. All reagents for E8 hESC culture were from Thermo Fisher Scientific.
For transgene inductions in hESCs or during differentiation, 1 μg/ml
doxycycline (dox, Sigma) and/or 0.5 μM Shield-1 (Clontech) were added to media,
where specified. For depletion of AID-fused proteins, auxin (indole-3-acetic acid
sodium salt, IAA, Sigma) was used at 100 μM (in H2O) unless otherwise specified.
For depletion of JAZ-fused proteins, coronatine (Cor, Sigma) was used at 50 μM (in
DMSO) in all experiments. DMSO was used as vehicle control for experiments
with Cor.
HEK-293T cell manipulation. HEK-293T cells were cultured in DMEM with 10%
fetal bovine serum (FBS, Corning), 1 mM sodium pyruvate, 2 mM L-glutamine and
PenStrep (all GIBCO)24. For JAZ degron testing, the cells were transfected with
vectors for expression of GFP fused to OsJAZ33, OsJAZ33-NLS or OsJAZ43. Len-
tivirus production, HEK-293T transfection and selection were carried out as in24.
The cells were then treated with either 50 μM Cor (Sigma) in DMSO or 0.1%
DMSO as control. GFP depletion was analysed using flow cytometry. FlowJo
(TreeStar) was used to calculate the geometric mean of GFP fluorescence intensity.
hPGCLC and DE induction. To induce hPGCLCs3, 4i hESCs were trypsinised,
filtered and plated into ultra-low cell attachment U-bottom 96-well plates (Corn-
ing, 7007) at 4000 cells/well density in 100 μl PGCLC medium5 (Table 2). For
induction of large quantities of hPGCLCs (for ChIP-seq and qPCR experiments),
six-well EZSPHERE microplates (ReproCELL) were used (500,000 cells/well in 3
mL PGCLC medium). The plates were centrifuged at 300 g for 3 min and placed
into a 37 °C 5% CO2 incubator until embryoid body (EB) collection for down-
stream analysis. Reporter fluorescence intensities were monitored daily throughout
differentiation using Olympus IX71 microscope.
For hPGCLC induction from E8 (conventional) hESCs5, preME competent
state was induced by seeding 200,000 trypsinised single cells per well of a
vitronectin-coated 12-well plate and culturing for 12 h in ME medium
(Supplementary Table 1). PreME cells were then trypsinised, filtred and induced
similar to 4i hESCs, as described above.
For DE induction5, ME was first obtained from E8 cells by 36-h exposure to ME
medium (Supplementary Table 1). ME was then washed with PBS followed by 48-h
culture in the DE medium (Supplementary Table 2).
Flow cytometry and fluorescence-activated cell sorting. Flow cytometry and
FACS were performed as in3. The gating strategy for hPGCLC identification is
shown in Supplementary Fig. 10. At least six EBs were washed in PBS and dis-
sociated with 0.25% Trypsin-EDTA for 10 min at 37 °C. Cells were washed,
resuspended in FACS buffer (3% FBS in PBS) and incubated with anti-AP and anti-
CD38 antibodies specified in Supplementary Table 3 for 30–60 min at 4 °C in the
dark. After washing, the cells were resuspended in FACS buffer with 0.1 µg/ml
DAPI and filtered through a 50 µm cell strainer. Flow cytometry was done using
BD LSR Fortessa, while FACS was performed with Sony SH100 Cell Sorter. Data
were analysed using FlowJo (Tree Star).
Isolation of gonadal hPGC by FACS. The collection and usage of human
embryonic tissues were approved by the National Research Ethics Service (REC 96/
085). Patients (who had already decided to undergo the termination of pregnancy
operation) fully and freely consented to donate the foetal tissues for medical and
academic research. Human genital ridges were dissected in PBS and separated from
the mesonephros followed by dissociation with TrypLE Express (Life Technologies)
at 37 °C for 20–40 min (depending on the tissue size) with pipetting every 5 min.
Cells were washed, resuspended in FACS buffer (3% FBS and 5 mM EDTA in PBS)
and incubated with anti-AP and anti-cKIT antibodies (specified in Supplementary
Table 3) for 15 min at room temperature with 10 rpm rotation in the dark. Cells
were then washed in FACS medium and filtered through a 35 µm cell strainer.
FACS was performed with Sony SH100 Cell Sorter and data were analysed using
FlowJo (Tree Star). Cell populations of interest were sorted onto Poly-L-Lysine
Slides (Thermo Scientific) and fixed in 4% PFA for IF analysis.
Immunofluorescence. For IF, hESCs were grown on ibiTreat eight-Well µ-Slides
(Ibidi) on MEFs (GlobalStem), washed with PBS and fixed with 4% paraf-
ormaldehyde (PFA, Thermo Fisher Scientific) in PBS at room temperature (RT) for
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10 min. This was followed by three washes in PBS and a 10-min permeabilisation
in 0.25% Triton X-100 (Sigma) in PBS. Next, the samples were incubated with the
blocking buffer (0.1% Triton X-100, 5% normal donkey serum (Stratech) and 1%
bovine serum albumin (BSA, Sigma)) for 30 min at RT. The samples were then
incubated with primary antibodies (Supplementary Table 3) diluted in the blocking
buffer overnight at 4 °C. The following day they were washed 3 times with the wash
buffer (0.1% Triton X-100 in PBS) and incubated with Alexa fluorophore (AF- 488,
568 and/or 647)-conjugated secondary antibodies (Invitrogen, used in 1:500 dilu-
tions in the blocking buffer) specific for the host species of the primary antibodies
for 1 h at RT in the dark. After three washes in the wash buffer, the samples were
incubated in PBS with 1 µg/ml DAPI for 10 min at RT. The samples were stored at
4 °C in the dark (up to 2 weeks) before imaging on Leica SP5 inverted confocal
microscope. The images were analysed using Fiji software.
hPGCLC-containing EBs were fixed on D4 (unless otherwise specified) using
4% PFA in PBS at 4 °C for 1–2 h. After two washes in PBS, the EBs were transferred
to 10% sucrose solution in PBS and stored at 4 °C for 1 day. This was followed by a
1-day incubation in 20% sucrose in PBS at 4 °C. Finally, the EBs were embedded in
OCT compound (CellPath), snap frozen on dry ice and stored at −80 °C until
cryosectioning. Cryosections of 8-μm thickness were made on Superfrost Plus
Micro slides (VWR) using a Leica Microsystems cryostat. Slides were stored at
−80 °C or processed immediately. For IF, slides were air-dried at RT for 1 h,
washed in PBS three times 5 min each and permeabilised in 0.1% Triton X-100 in
PBS for 30 min at RT. The cryosections on each slide were then circumscribed
using ImmEdge Hydrophobic Barrier Pen (Vector Labs) and blocking solution (as
above) was added for 30 min at RT. Samples were then incubated with primary and
secondary antibodies (Supplementary Table 3) as specified for hESC IF above, but
1 μg/ml DAPI was added to the secondary antibody mixtures. Finally, the slides
were washed in the wash buffer twice and in PBS once and mounted with Prolong
Gold Antifade Reagent (Molecular Probes). The images were acquired using Leica
SP5 confocal microscope and analysed using Fiji software58.
A custom script for Fiji written by Dr Richard Butler (Gurdon Institute, University
of Cambridge, UK) was used to segment nuclei with an area of 30–300 μm2 in the
DAPI channel and measure fluorescence intensity in other channels. The script is
available at https://github.com/gurdon-institute/SOX17_PRDM14_Measurement.
The data was then manually processed in Microsoft Excel to filter pluripotent cells
(NANOG or OCT4 fluorescence intensity >50) where applicable and to calculate
mean fluorescence intensities. Statistical analyses were performed using GraphPad
Prism 7.
Plasmid constructions and cell line establishment. For gene targeting, CRISPR-
Cas9 approach was used25. Annealed oligos (Supplementary Data 5) encoding
corresponding gRNAs were ligated into pX330 vector25 digested with BbsI. gRNA
sequences were chosen using the MIT CRISPR tool (http://www.genome-
engineering.org/crispr/) to be located close to the stop codon (to enable C-terminal
fusions in PRDM14-T2A-Venus, PRDM14-AID-Venus, PRDM14-JAZ-Venus and
SOX17-AID-Venus). The chosen protospacer sequences were as follows:
GTGAAGACTACTAGCCCTGC for PRDM14 and GACGTGTGACAGGTCCC
TGA for SOX17 (Naoko Irie, personal communication).
All other plasmids, including donor vectors for homology-directed repair were
generated using In-Fusion cloning (Clontech) according to manufacturer’s
recommendations, but scaling down the reaction to a total volume of 5 μl. Primers
used for cloning are specified in Supplementary Data 5.
For knock-ins either electroporation or lipofection was used. For
electroporation, ~250,000 trypsinised hESCs were resuspended in 600 μl PBS+
Ca2++Mg2+ containing 50 μg gRNA plasmid and 50 μg homologous repair donor
plasmid and electroporated in a 0.4-cm cuvette using Gene Pulser Xcell System
(Bio-Rad) with a single 20 ms square-wave pulse (250 V). Lipofections were
performed using 2 μg gRNA plasmid and 2 μg donor construct in OptiMEM
medium (GIBCO) and Lipofectamine Stem reagent (Invitrogen) according to
manufacturer’s recommendations. The volume of lipofectamine in microlitres was
equal to the total amount of DNA in micrograms. For lipofection of PiggyBac
transgenes a total of 1–5 μg DNA/100,000 cells was used, with the amount of
PiggyBac transposase (PBase)-encoding plasmid equal to that of PiggyBac-
delivered transgenes combined (in μg). Transfected cells were seeded onto drug-
resistant DR4 MEFs (SCI) in 4i medium (ROCKi added for the first 24 h; selection
was initiated 48 h after transfection).
After selection, individual clones were picked, expanded and genotyped using
PCR. For this, genomic DNA was first extracted from cell pellets in the lysis buffer
(10 mM Tris pH 8.0, 100 mM NaCl, 10 mM EDTA and 0.5% SDS; Proteinase K
(PK) was added immediately prior to lysis at a final concentration of 0.2 mg/ml) at
56 °C for 4 h—overnight, followed by PK inactivation at 98 °C for 10 min. The
supernatant was used directly in genotyping PCR performed with LongAmp (NEB)
or PrimeStar GXL (Clontech) polymerase according to the manufacturers’
protocols. Primers used for genotyping are specified in Supplementary Data 5. In
the case of transgenes expression, homogeneity and leakiness of induction was
checked by IF.
For knock-ins (PRDM14-T2A-Venus, PRDM14-AID-Venus, PRDM14-JAZ-
Venus and SOX17-AID-Venus) correct targeting in homozygous (by genotyping)
clones was confirmed by Sanger sequencing. This was followed by the removal of
the Rox-flanked puromycin resistance cassette by transient transfection with 1 μg
of Dre-recombinase-encoding plasmid59. Two days of hygromycin B selection (50
μg/ml) were followed by 2 days of negative selection using FIAU (200 nM)28. The
obtained clones were again genotyped by PCR and sequenced to confirm antibiotic
cassette excision. Venus intensity and homogeneity were then verified using Flow
cytometry and IF.
For generation of cell lines that deplete PRDM14 upon IAA supplementation,
AID-Venus was added at the C-terminus of PRDM14 using CRISPR (see above).
This was followed by the addition of TIR1 transgene (pPB-CAG-OsTir1-myc-
IRES-HygR or pPB-CAG-OsTir1-V5-T2A-Puro) by lipofection, along with
pPBase. TIR1 cDNA and the 44-amino-acid AID sequence34 were kindly provided
by Dr Elphège Nora.
For generation of cell lines that deplete PRDM14 upon Cor supplementation,
JAZ-Venus was added at the C-terminus of PRDM14 using CRISPR (see above).
This was followed by the addition of COI1B transgene (pPB-CAG-HA-
FboxOsTir1-OsCoi1b-IRES-HygR) by lipofection, along with pPBase.
For PRDM14-DD rescue, PRDM14-AID-Venus+ TIR1 hESCs were co-
lipofected with 0.05 μg pPB-CAG-myc-PRDM14-DD-IRES-HygR (low DNA
amount was used to limit transgene copy number), 0.5 μg pPB-CAG-OsTir1-V5-
T2A-Puro (to avoid TIR1 excision by PBase) and 0.55 μg PBase.
Reverse-transcription quantitative PCR (qPCR). Total RNA was extracted using
the RNeasy Mini Kit (QIAGEN) from unsorted cells or using Arcturus PicoPure
(Thermo Fisher Scientific) from at least 1000 sorted cells. cDNA was synthesised
using the QuantiTect Reverse-Transcription Kit (QIAGEN). qPCR was performed
on a QuantStudio 12K Flex Real-Time PCR machine (Applied Biosystems) using
SYBR Green JumpStart Taq ReadyMix (Sigma) and specific primers (Supple-
mentary Data 5). The ΔΔCt method was used for quantification of gene expression.
Table 2 hPGCLC medium composition.
Component Final concentration Supplier
Advanced RPMI 1640 – GIBCO
B27 supplement 1% GIBCO
L-glutamine 2 mM GIBCO
Nonessential amino acids 0.1 mM GIBCO
Penicillin–streptomycin 100 U/ml (Penicillin) GIBCO
0.1 mg/ml
(Streptomycin)
BMP2 500 ng/ml SCI
Human LIF 1 μg/ml SCI
SCF 100 ng/ml R&D systems
EGF 50 ng/ml R&D systems
ROCK inhibitor (Y-27632) 10 μM TOCRIS
bioscience
Poly-vinyl alcohol (PVA, 10%) 0.25% Sigma
Table 1 4i medium composition.
Component Final
concentration
Supplier
Knockout DMEM – GIBCO
Knockout serum
replacement (KSR)
20% GIBCO
L-glutamine 2mM GIBCO
Nonessential amino acids 0.1 mM GIBCO
2-mercaptoethanol 0.1 mM GIBCO
Penicillin–streptomycin 100 U/ml
(penicillin)
GIBCO
0.1 mg/ml
(streptomycin)
Human LIF 20 ng/ml Stem Cell
Institute (SCI)
bFGF 8 ng/ml SCI
TGF-β1 1 ng/ml Peprotech
CHIR99021 (CH) 3 μM Miltenyi Biotec
PD0325901 (PD) 1 μM Miltenyi Biotec
SB203580 (SB) 5 μM TOCRIS bioscience
SP600125 (SP) 5 μM TOCRIS bioscience
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Statistical analyses were performed using Microsoft Excel and/or GraphPad
Prism 7.
RNA-sequencing. RNA-seq was performed on PRDM14-AID-Venus competent 4i
hESCs and hPGCLCs induced therefrom. Two biological replicates were used for
each condition. For IAA-sensitive cells, two clones (cl11 and cl21) from the same
hESC passage or the same hPGCLC induction were used as replicates. For the
parental (no TIR1) control, the same cell line was used at different passages or
inductions to yield two independent replicates. In total, 10,000 AP+ 4i hESCs or
10,000 NANOS3-tdTomato+AP+ hPGCLCs (with the exception of hPGCLC cl21
replicate, where 3000 cells were used) were sorted directly into 100 μl of extraction
buffer from the PicoPure RNA Isolation Kit (Applied Biosystems) for subsequent
total RNA extraction according to manufacturer’s protocol. RNA was stored at
−80 °C and its quality and quantity were checked by the Agilent RNA 6000 Pico
Kit with Bioanalyzer (Agilent Technologies) and Qubit (Thermo Fisher Scientific).
RNA-seq library was prepared from 10 ng input RNA using the end-to-end Trio
RNA-seq library prep kit (Nugen) following the manufacturer’s protocol but
omitting the AnyDeplete step. In short, the protocol contains the following steps:
DNAse treatment to remove DNA from RNA; first strand and second strand
cDNA synthesis to produce the reverse complement of the input RNAs; cDNA
purification using Agencourt AMPure XP beads (Beckman Coulter); single-primer
isothermal amplification to stoichiometrically amplify cDNAs; enzymatic frag-
mentation and end repair; sequencing adaptor (index) ligation; product purifica-
tion using AMPure beads; library amplification (four cycles were used); library
purification using AMPure beads. Libraries were then quantified by qPCR using
the NEBNExt Library Quant Kit (NEB) for Illumina on QuantStudio 6 Flex Real-
Time PCR System (Applied Biosystems). Fragment size distribution and the
absence of adaptor dimers was checked using Agilent TapeStation 2200 and High
Sensitivity D1000 ScreenTape. Finally, RNA-seq libraries were subjected to single-
end 50 bp sequencing on HiSeq 4000 sequencing system (Illumina). Twenty-four
indexed libraries (including samples from this work and eight others) were mul-
tiplexed together and sequenced in two lanes of a flowcell, resulting in >30 million
reads per sample.
RNA-seq analysis. The library sequence quality in demultiplexed fastq files was
checked by FastQC (v0.11.5)60 and the low-quality reads and adaptor sequences
were removed by Trim Galore (v0.4.1)61 using the default parameters. The pre-
processed RNA-seq reads were mapped to the human reference genome (UCSC
GRCh38/hg38) using STAR (2.6.0a)62 (–outFilterMismatchNoverLmax 0.05 –
outMultimapperOrder Random –winAnchorMultimapNmax 100 –out-
FilterMultimapNmax 100) guided by the ENSEMBL (Release 87) gene models.
Read counts per gene were extracted using TEtranscripts63 and normalised by
DEseq2 in R64. Differential expression analysis was also performed using DEseq2.
The resulting gene expression table (Supplementary Data 1) was used for down-
stream analyses in Microsoft Excel and R. Pearson’s correlation analysis was per-
formed using the R cor command. Unsupervised hierarchical clustering was
performed using the R hclust function with (1—Pearson’s correlation coefficient)
as distance measures. The R prcomp function was used for PCA. GSEA was per-
formed using the GSEA software by the Broad Institute65. GO analysis was per-
formed using DAVID66.
For comparative differential expression analysis of PRDM14 depletion in
hPGCLCs and TFAP2C and PRDM1 KOs from20 the samples were identically pre-
processed and mapped to the human reference genome (UCSC GRCh38/hg38),
sequencing reads were re-normalised together using DEseq2 to generate a new
integrated gene expression table (Supplementary Data 2). A similar procedure was
performed for comparisons with mouse Prdm14 KO from11, where processed reads
were mapped to the mouse reference genome (UCSC GRCm38/mm10), and high-
confidence human–mouse one-to-one orthology assignments for protein-coding
genes were obtained from ENSEMBL (Release 87) (Supplementary Data 4). Venn
diagrams were plotted using VennPainter67 and p values for two overlapping
datasets were calculated using a generalised hypergeometric test for multiple
samples68. For the co-expression analysis of DEGs, the gene-based Pearson’s
correlation coefficients were calculated for PRDM14-AID-Venus competent hESC
and hPGCLC samples using R. All pairwise correlations r < 0.8 between genes were
removed. The matrix was imported as an adjacency matrix into the R igraph
package69, and the Louvain method for community detection was performed on
the resulting graph. For comparison with microarray data13, the published data was
normalised, log2-transformed and the differential expression was evaluated using
the R limma package70.
Chromatin immunoprecipitation (ChIP) and ChIP-seq. ChIP was performed
using the SimpleChIP Enzymatic Chromatin IP Kit (with Magnetic Beads) from
Cell Signalling Technology (CST) following manufacturer’s recommendations with
modifications. Recipes for all buffers are provided in Table 3. The following
samples were included in the analysis (one replicate per condition): 4i hESCs (cl11
no IAA), 4i+ IAA hESCs (cl11+ IAA) and hPGCLCs (cl11 and cl21 pooled; no
IAA). For each ChIP 2.5 million unsorted 4i hESCs or 4 million unsorted
hPGCLCs (D4 EBs containing 60–70% PGCLCs as assessed by flow cytometry)
were used. The cells were washed in PBS, filtered through 50 μm strainer and fixed
in 1% formaldehyde at RT for 10 min. Formaldehyde was quenched by adding 450
μl of 10× glycine at RT for 10 min, followed by centrifugation at 500 g, 4 °C for 5
min. The cells were then washed twice in ice-cold PBS with protease inhibitor
cocktail (PIC) and the pellets were snap frozen on dry ice and stored at −80 °C. To
prepare nuclei, cells were thawed on ice, washed in ice-cold buffers A and B,
resuspended in 100 μl buffer B and transferred to a thin-walled Diagenode 1.5 ml
tubes. Next, 0.35 μl micrococcal nuclease (MNase) was added and the suspension
was incubated for 23 min at 37 °C, shaking at 800 rpm to enzymatically digest the
chromatin. The addition of 10 μl 0.5 M EDTA for 2 min on ice was used to stop the
digestion. Next, the nuclei were pelleted at 15,500 g, 4 °C for 1 min, resuspended in
100 μl of ChIP buffer 1 and kept on ice for 10 min, followed by sonication (3 × 30 s
on/off, high output) using Bioruptor sonicator (Diagenode). The lysate was cleared
by centrifugation at 9200 g, 4 °C for 10 min and transferred to a fresh DNA LoBind
1.5 ml tube (Eppendorf). For ChIP, 400 μl ChIP buffer two was added for a total of
500 μl/sample; 10 μl were removed and stored at −80 °C to serve as 2% input.
Antibodies (3 μl PRDM14 ABD121 or 0.5 μl GFP ab290, see Supplementary
Table 3) were then added to each immunoprecipitation (IP) reaction and IPs were
incubated overnight rotating at 10 rpm, 4 °C.
Equal volumes of Protein A and Protein G-conjugated magnetic beads
(Invitrogen) were combined (for a total of 20 μl per IP) in a DNA LoBind 1.5 ml
tube, washed in 200 μl blocking buffer, and incubated with 500 μl blocking buffer
for 1 h rotating at 10 rpm, 4 °C. The tubes were placed on a magnetic rack
(Diagenode) to remove the supernatant and another 1-h incubation was
performed. Then the supernatant was removed, the beads were resuspended in 20
μl blocking buffer and stored at 4 °C for up to 24 h until the use in ChIP.
After overnight IP, 20 μl of pre-blocked Protein A/G beads were added to each
sample, followed by rotation at 10 rpm, 4 °C for 2 h. The tubes were placed on a
magnetic rack and the supernatant was removed. The beads were then washed three
times with 1ml low-salt buffer (each wash involved a 5-min rotation at 10 rpm, 4 °C),
Table 3 Buffer recipes for ChIP.
Buffer A 1x
Buffer A stock, µl 250
H2O, µl 750
DTT, µl 0.5
PIC, µl 5
Buffer B 1x
Buffer B stock, µl 275
H2O, µl 825
DTT, µl 0.55
ChIP buffer 1 1x
ChIP buffer stock, µl 10
H2O, µl 90
PIC, µl 0.5
ChIP buffer 2 1x
ChIP buffer stock, µl 40
H2O, µl 360
PIC, µl 2
tRNA (Sigma) [10 mg/ml], µl 2
Elution 1x
Elute buffer, µl 25
H2O, µl 25
Blocking buffer 1x
ChIP buffer (CST), µl 150
H2O, µl 1110
PIC (Roche), µl 75
BSA (Sigma) (10%), µl 150
tRNA (Sigma) [10 mg/ml], µl 15
Low salt 1x
ChIP buffer (CST), µl 300
H2O, µl 2700
High salt 1x
ChIP buffer (CST), µl 100
H2O, µl 900
NaCl, µl 70
LiCl Wash buffer For 250mL
20mM Tris-HCl pH 8.0, ml 5 ml of 1M
2mM EDTA, ml 1 ml of 0.5M
250mM LiCl, g 2.65 g
1% NP-40, ml 2.5 ml
1% Deoxycholate, g 2.5 g
H2O, ml 241.5 ml
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-15042-0 ARTICLE
NATURE COMMUNICATIONS |         (2020) 11:1282 | https://doi.org/10.1038/s41467-020-15042-0 | www.nature.com/naturecommunications 15
once with high-salt buffer and once with LiCl buffer. Finally, the beads were
resuspended in 50 μl elution buffer and transferred to 0.2ml PCR stripes. The inputs
were thawed on ice and supplemented with 50 μl elution buffer. All samples were
incubated at 65 °C, 110 g for 30min to elute the protein–DNA complexes from the
beads. The stripe was then placed onto a magnetic rack and the eluate was transferred
into a fresh 0.2ml PCR stripe to which 2 μl 5M NaCl and 2 μl PK (10mg/ml) were
added. The samples were then incubated at 65 °C, 110 g for 2 h for decrosslinking.
Finally, for the use in ChIP-qPCR, DNA was purified using MinElute columns
(QIAGEN) following the manufacturer’s protocol. Alternatively, for ChIP-seq
library preparation, DNA was purified using Agencourt AMPure XP beads
(Beckman Coulter) as follows. 1.8× volume of AMPure beads were mixed with each
sample, incubated for 10 min to bind DNA to the beads and washed 2 × 30 s with
200 μl 80% ethanol using a magnetic rack. The beads were air-dried for 5–10 min to
reach complete ethanol evaporation. Thirty three microlitres of elution buffer (10
mM Tris-HCl, pH 8.0–8.5) was added and incubated with the beads for 2 min to
elute the ChIP DNA. The PCR stripe was placed on the magnetic rack and 30 μl of
eluate was transferred into fresh tubes.
For ChIP-seq libraries were prepared using the KAPA HyperPrep Kit following
the manufacturer’s instructions. Briefly, the protocol contains the following steps:
end-repair and A-tailing; sequencing adaptor (index) ligation; product purification
using AMPure beads; library amplification using the KAPA real-time Library
Amplification Kit (11 cycles were used for ChIP libraries and 7 for input libraries to
achieve similar concentration range); product purification using AMPure beads.
Libraries were then quantified by qPCR using the NEBNExt Library Quant Kit for
Illumina (NEB) on QuantStudio 6 Flex Real-Time PCR System (Applied
Biosystems). Fragment size distribution and the absence of adaptor dimers was
checked using Agilent TapeStation 2200 and High Sensitivity D1000 ScreenTape.
Finally, ChIP-seq libraries were subjected to single-end 50 bp sequencing on HiSeq
4000 sequencing system (Illumina). Eight indexed libraries were multiplexed in one
lane of a flowcell, resulting in >20 million reads per sample.
ChIP-seq analysis. The library sequence quality in demultiplexed fastq files was
checked by FastQC (v0.11.5)60 and the low-quality reads and adaptor sequences were
removed by Trim Galore (v0.4.1)61 using the default parameters. The trimmed ChIP-
seq reads were aligned to the human reference genome (UCSC hg38) by the
Burrows–Wheeler Aligner (0.7.15-r1142-dirty)71. Samtools (version: 1.3.1)72 was used
to remove unmapped and low-mapping quality reads (options: view -F 4 -q 20).
Subsequently, duplicated reads and reads mapped to unlocalised contig (random),
unplaced contigs (ChrUn) and blacklisted regions (obtained from http://mitra.
stanford.edu/kundaje/akundaje/release/blacklists/hg38-human/) were removed using
Samtools rmdup. This was followed by preliminary peak calling using macs2 call-
peak73 against the corresponding inputs (options: -g 3e9 –keep-dup all). Percentage of
reads in peaks was calculated using featureCounts74 and visualised with multiQC75.
Before peak calling, to compare the number of peaks between the three high-quality
samples, the library size for all libraries was downsampled to 25 million reads. Peaks
were then called again using macs2 callpeak against the corresponding inputs
(options: -g 3e9 –keep-dup all –nomodel –extsize 157). The resultant peak files of the
three samples were merged to generate a consensus set of 6486 peaks using bedtools
merge (options: -d 100)76. The consensus peaks were processed and clustered by
DeepTools computeMatrix and plotHeatmap77. Peak annotation, motif enrichment
and differential peak analyses were performed by HOMER41. DeepTools bam-
Coverage (options: -extendReads 157 –binSize 10 –normalizeUsing CPM –ignor-
eForNormalization chrX chrY) was used to generate bigwig file for visualisation in
Integrative Genomics Viewer78. The integrated ChIP-seq and RNA-seq table (Sup-
plementary Data 3) was generated using R to correlate changes in gene expression to
PRDM14 binding. Venn diagrams were plotted using the R/Bioconductor ChIPseeker
package79.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
All relevant data, including full plasmid sequences, are available from the authors on
request. The source data underlying experimental results for Fig. 1d is provided as a
Source Data file. High-throughput sequencing (RNA-seq and ChIP-seq) data have been
deposited at the NCBI Gene Expression Omnibus (GEO) database and can be found at
the following address: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE138675.
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